SCHEMBL4037660

SCHEMBL4037660

Cc1nc(NC2CCNCC2)cc(-n2nc(Nc3ccccc3)nc2N)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAK4 O96013 2/20 0.41
FLT3 P36888 10/20 0.41
KIT P10721 6/20 0.41
ROCK1 Q13464 1/20 0.39
AXL P30530 4/20 0.38
KDR P35968 2/20 0.38
AURKA O14965 1/20 0.38
JAK2 O60674 1/20 0.38
IRAK4 Q9NWZ3 1/20 0.38
CTSL P07711 2/20 0.38
CTSB P07858 2/20 0.38
CTSS P25774 2/20 0.38
CTSK P43235 2/20 0.38
INSR P06213 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
KHK P50053 1/20 0.37
PLK4 O00444 1/20 0.36
ABL1 P00519 1/20 0.36
LCK P06239 1/20 0.36
LYN P07948 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4044430 0.90 MEN1 (0.44) FLT3KITAXLINSR
SCHEMBL12781256 0.87 CCNB2 (0.41) PAK4FLT3KITROCK1AXL
SCHEMBL4040144 0.84 HRH3 (0.48) FLT3KITROCK1HRH3
SCHEMBL2086901 0.83 FLT3 (0.47) FLT3KITAXLAURKAJAK2
SCHEMBL12781261 0.83 CCNB2 (0.41) PAK4FLT3KITROCK1AXL
SCHEMBL4037526 0.79 FLT3 (0.47) FLT3KITAXLAURKAJAK2
SCHEMBL4040465 0.79 LMNA (0.50) FLT3KITAXLAURKAJAK2
SCHEMBL4043348 0.77 FLT3 (0.47) FLT3KITAXLKDRAURKA
SCHEMBL12781962 0.77 FLT3 (0.48) FLT3KITAXLAURKAJAK2
SCHEMBL12779081 0.77 FLT3 (0.48) FLT3KITAXLAURKAJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
EP-1463728-B1 FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION BRISTOL MYERS SQUIBB CO (US) 2009-01-14 EP disclosed
EP-1562589-B1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-01-07 EP disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K5 PAK4 164/4885FLT3 220/4885KIT 1144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.